JP2018516092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516092A5 JP2018516092A5 JP2018503725A JP2018503725A JP2018516092A5 JP 2018516092 A5 JP2018516092 A5 JP 2018516092A5 JP 2018503725 A JP2018503725 A JP 2018503725A JP 2018503725 A JP2018503725 A JP 2018503725A JP 2018516092 A5 JP2018516092 A5 JP 2018516092A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- target
- rlx
- amino acid
- mgswx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 129
- 229920001184 polypeptide Polymers 0.000 claims description 123
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 123
- 230000027455 binding Effects 0.000 claims description 104
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 33
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 24
- 235000001014 amino acid Nutrition 0.000 claims description 24
- 210000002865 immune cell Anatomy 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- 230000009870 specific binding Effects 0.000 claims description 16
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 15
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 8
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 8
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 230000004068 intracellular signaling Effects 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- -1 DBDpp Proteins 0.000 claims description 5
- 230000000139 costimulatory effect Effects 0.000 claims description 5
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 claims description 4
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 3
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 3
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 3
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 3
- 102000002698 KIR Receptors Human genes 0.000 claims description 3
- 108010043610 KIR Receptors Proteins 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 3
- 102000003735 Mesothelin Human genes 0.000 claims description 3
- 108090000015 Mesothelin Proteins 0.000 claims description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 3
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- 238000012737 microarray-based gene expression Methods 0.000 claims description 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 230000005809 anti-tumor immunity Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 description 13
- 230000001472 cytotoxic effect Effects 0.000 description 13
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068754A JP7244567B2 (ja) | 2015-04-06 | 2021-04-15 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2023007753A JP2023052563A (ja) | 2015-04-06 | 2023-01-23 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2024049923A JP2024075751A (ja) | 2015-04-06 | 2024-03-26 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143772P | 2015-04-06 | 2015-04-06 | |
| US62/143,772 | 2015-04-06 | ||
| PCT/US2016/025868 WO2016164305A1 (en) | 2015-04-06 | 2016-04-04 | De novo binding domain containing polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021068754A Division JP7244567B2 (ja) | 2015-04-06 | 2021-04-15 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516092A JP2018516092A (ja) | 2018-06-21 |
| JP2018516092A5 true JP2018516092A5 (enExample) | 2019-05-09 |
| JP6871232B2 JP6871232B2 (ja) | 2021-05-12 |
Family
ID=57072017
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503725A Active JP6871232B2 (ja) | 2015-04-06 | 2016-04-04 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2018503726A Active JP6873101B2 (ja) | 2015-04-06 | 2016-04-04 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2021068754A Active JP7244567B2 (ja) | 2015-04-06 | 2021-04-15 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2023007753A Withdrawn JP2023052563A (ja) | 2015-04-06 | 2023-01-23 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2024049923A Pending JP2024075751A (ja) | 2015-04-06 | 2024-03-26 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018503726A Active JP6873101B2 (ja) | 2015-04-06 | 2016-04-04 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2021068754A Active JP7244567B2 (ja) | 2015-04-06 | 2021-04-15 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2023007753A Withdrawn JP2023052563A (ja) | 2015-04-06 | 2023-01-23 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
| JP2024049923A Pending JP2024075751A (ja) | 2015-04-06 | 2024-03-26 | 新規結合ドメイン含有ポリペプチドおよびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US10647775B2 (enExample) |
| EP (3) | EP3903804A1 (enExample) |
| JP (5) | JP6871232B2 (enExample) |
| KR (2) | KR20250048140A (enExample) |
| CN (4) | CN107921090A (enExample) |
| AU (4) | AU2016246426B2 (enExample) |
| BR (1) | BR112017021308A2 (enExample) |
| CA (2) | CA2981616C (enExample) |
| CY (1) | CY1124453T1 (enExample) |
| DK (2) | DK3280432T3 (enExample) |
| EA (1) | EA201792226A1 (enExample) |
| ES (2) | ES2901273T3 (enExample) |
| HR (1) | HRP20210498T1 (enExample) |
| HU (1) | HUE054435T2 (enExample) |
| IL (2) | IL254907B (enExample) |
| LT (1) | LT3280432T (enExample) |
| MX (2) | MX387517B (enExample) |
| PH (1) | PH12017501834B1 (enExample) |
| PL (1) | PL3280432T3 (enExample) |
| PT (1) | PT3280432T (enExample) |
| RS (1) | RS61907B1 (enExample) |
| SG (2) | SG11201708257UA (enExample) |
| SI (1) | SI3280432T1 (enExample) |
| SM (1) | SMT202100285T1 (enExample) |
| WO (3) | WO2016164305A1 (enExample) |
| ZA (1) | ZA201706875B (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| SG11201708257UA (en) | 2015-04-06 | 2017-11-29 | Subdomain Llc | De novo binding domain containing polypeptides and uses thereof |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018075586A1 (en) * | 2016-10-18 | 2018-04-26 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| CA3053275A1 (en) * | 2017-02-10 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Proteins binding psma, nkg2d and cd16 |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| CN121343934A (zh) | 2017-05-10 | 2026-01-16 | 制药五有限责任公司 | 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒 |
| CN107216395B (zh) * | 2017-07-03 | 2018-07-20 | 上海科医联创生物科技有限公司 | 一种tm4sf1特异性嵌合抗原受体及其应用 |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| IL273484B2 (en) * | 2017-09-23 | 2025-12-01 | Memorial Sloan Kettering Cancer Center | A33 antibody compositions and methods of using the same in radioimmunotherapy |
| EP3706801B1 (en) | 2017-11-08 | 2026-01-14 | L.E.A.F Holdings Group LLC | Platinum complexes and uses thereof |
| TWI701259B (zh) * | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | ４﹘１ｂｂ抗體及其製備方法和應用 |
| AU2018368431B2 (en) * | 2017-11-14 | 2024-03-21 | Arcellx, Inc. | Multifunctional immune cell therapies |
| SI3710067T1 (sl) * | 2017-11-14 | 2026-01-30 | Arcellx, Inc. | Polipeptidi, ki vsebujejo D-domeno, in njihova uporaba |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019157129A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pralatrexate and uses thereof |
| CA3090391A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| WO2019157133A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| CA3090384A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| JP7491573B2 (ja) | 2018-02-07 | 2024-05-28 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化メトトレキセートおよびその使用 |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| US12290518B2 (en) | 2018-02-14 | 2025-05-06 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| US12048767B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| US20210017248A1 (en) * | 2018-03-16 | 2021-01-21 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| MX2020011844A (es) | 2018-05-08 | 2021-04-13 | Amgen Inc | Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles. |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| CN113164570B (zh) * | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| GB201903479D0 (en) * | 2019-03-14 | 2019-05-01 | Univ Oxford Innovation Ltd | Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| CN113661240B (zh) * | 2019-04-02 | 2024-11-05 | 伊莱利利公司 | 选择和检测结合肽的方法 |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN111848733B (zh) * | 2019-04-30 | 2024-03-12 | 上海细胞治疗集团有限公司 | 一种多肽组合物及疫苗 |
| WO2020242988A2 (en) * | 2019-05-24 | 2020-12-03 | Avitide, Inc. | Affinity agents |
| CA3142339A1 (en) | 2019-05-31 | 2020-12-03 | Rubryc Therapeutics, Inc. | Machine learning-based apparatus for engineering meso-scale peptides and methods and system for the same |
| CA3149914A1 (en) | 2019-08-06 | 2021-02-11 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
| JPWO2021100585A1 (enExample) * | 2019-11-20 | 2021-05-27 | ||
| WO2021115333A1 (zh) * | 2019-12-10 | 2021-06-17 | 苏州克睿基因生物科技有限公司 | 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用 |
| JP7752621B2 (ja) * | 2020-02-17 | 2025-10-10 | ミルテニー バイオテック ベー．フェー． ウント コー． カー・ゲー | 腫瘍微小環境細胞に対するキメラ抗原受容体（ｃａｒ）を有するパーソナライズされた細胞を提供する方法 |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| CN111560391B (zh) * | 2020-05-21 | 2022-02-11 | 北京大学 | 一种蛋白质异质索烃的生物合成方法 |
| CN111732635B (zh) * | 2020-06-22 | 2022-03-22 | 中国医学科学院基础医学研究所 | 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用 |
| EP4175656A4 (en) * | 2020-07-03 | 2024-10-16 | The Trustees of Columbia University in the City of New York | POLYFUNCTIONAL ORTHOGONAL PROTEIN CHIMERA |
| CN114380907B (zh) * | 2020-10-16 | 2024-06-18 | 中国科学院上海药物研究所 | 靶向cmtm6的纳米抗体及其制备方法和应用 |
| CA3208273A1 (en) * | 2021-01-20 | 2022-07-28 | Coding Bio Limited | Methods for high throughput screening of chimeric antigen receptors |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| BR112023019689A2 (pt) | 2021-03-26 | 2023-10-31 | Arcellx Inc | Terapias multifuncionais de célula imunológica |
| CN118679180A (zh) * | 2021-11-15 | 2024-09-20 | 阿奇利克斯股份有限公司 | 包含d结构域的多肽及其用途 |
| JP2025508721A (ja) * | 2022-02-18 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | 細胞表面受容体のエピトープ操作 |
| JP2025509573A (ja) * | 2022-03-17 | 2025-04-11 | シンギュラー イミューン インコーポレイテッド | 組換え融合タンパク質の組成物及びｃａｒ免疫細胞を作製するためのその使用方法 |
| CN119365491A (zh) * | 2022-04-27 | 2025-01-24 | 得克萨斯大学体系董事会 | 基于cd30铰链和/或跨膜结构域的嵌合抗原受体 |
| CN115028689B (zh) * | 2022-06-15 | 2023-05-30 | 浙江东方基因生物制品股份有限公司 | 特异性检测hpv6和hpv11的双特异性检测试剂盒 |
| CN116380854B (zh) * | 2023-03-06 | 2025-05-30 | 上海电力大学 | 一种基于荧光光谱快速检测水中微塑料污染的方法 |
| WO2024254346A1 (en) * | 2023-06-07 | 2024-12-12 | The Broad Institute, Inc. | Engineered viral like particles (evlps) for the selective transduction of target cells |
| WO2025122460A1 (en) * | 2023-12-04 | 2025-06-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| EP0934526B1 (en) | 1996-10-08 | 2003-01-08 | U-BISys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
| US7763258B2 (en) | 1997-05-20 | 2010-07-27 | The Trustees Of The University Of Pennsylvania | Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins |
| DE19802708A1 (de) | 1998-01-24 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren |
| ID26964A (id) | 1998-02-19 | 2001-02-22 | Xcyte Therapies Inc | Komposisi dan metode untuk pengaturan pengaktifan limfosit |
| US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
| EP1054018B1 (en) | 1999-05-18 | 2009-01-28 | Dyax Corp. | Fab fragment libraries and methods for their use |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US7608681B2 (en) | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| NZ523912A (en) | 2000-07-31 | 2005-03-24 | Biolex Inc | Expression of biologically active polypeptides in duckweed |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| CA2471551C (en) | 2001-12-27 | 2014-09-30 | Glycofi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
| AU2003209272A1 (en) | 2002-01-16 | 2003-09-02 | Zyomyx, Inc. | Engineered binding proteins |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| CA2478294C (en) | 2002-03-19 | 2013-09-03 | Plant Research International B.V. | Gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) expression in plants |
| AU2003260786B2 (en) | 2002-09-06 | 2008-03-13 | Isogenica Limited | In vitro peptide expression libraray |
| EP1539966B1 (en) | 2002-09-12 | 2010-06-30 | Greenovation Biotech GmbH | Protein production method |
| AU2003294912B2 (en) | 2002-12-20 | 2009-06-04 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| AU2004271200A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| WO2005044982A2 (en) | 2003-09-05 | 2005-05-19 | Oregon Health & Science University | Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| WO2007019376A2 (en) | 2005-08-03 | 2007-02-15 | Rq Bioscience, Inc. | Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| WO2008052043A2 (en) | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
| GB0907251D0 (en) | 2009-04-28 | 2009-06-10 | Univ Leiden | Coplymers |
| US20120172419A1 (en) | 2009-09-15 | 2012-07-05 | Medical College Of Wisconsin Research Foundation Inc. | Reagents and methods for modulating cone photoreceptor activity |
| US10023657B2 (en) * | 2010-10-01 | 2018-07-17 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012167109A2 (en) | 2011-06-03 | 2012-12-06 | Massachusetts Eye & Ear Infirmary | Rpgrip1 gene therapy for leber congenital amaurosis |
| WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| CN104640983A (zh) * | 2012-09-21 | 2015-05-20 | 株式会社钟化 | 亲和分离基质用蛋白质配体 |
| WO2014138805A1 (en) * | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| US9840539B2 (en) * | 2013-03-14 | 2017-12-12 | University Of Washington Through Its Center For Commercialization | High affinity digoxigenin binding proteins |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| GB201306634D0 (en) | 2013-04-11 | 2013-05-29 | Univ Bristol | Cage-like particles |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| LT3137497T (lt) | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
| SG11201708257UA (en) | 2015-04-06 | 2017-11-29 | Subdomain Llc | De novo binding domain containing polypeptides and uses thereof |
| KR20160126340A (ko) | 2015-04-23 | 2016-11-02 | 삼성전자주식회사 | 3중-나선 다발 단백질 및 이의 용도 |
| JP6901493B2 (ja) | 2015-11-13 | 2021-07-14 | アメリカ合衆国 | 抗ｂｃｍａポリペプチド及びタンパク質 |
| US20190365806A1 (en) | 2016-11-02 | 2019-12-05 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
| CN107254447B (zh) | 2017-06-01 | 2020-10-16 | 刘未斌 | Anti AFP CAR-T细胞及其制备方法和应用 |
| AU2018368431B2 (en) | 2017-11-14 | 2024-03-21 | Arcellx, Inc. | Multifunctional immune cell therapies |
| SI3710067T1 (sl) | 2017-11-14 | 2026-01-30 | Arcellx, Inc. | Polipeptidi, ki vsebujejo D-domeno, in njihova uporaba |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| BR112023019689A2 (pt) | 2021-03-26 | 2023-10-31 | Arcellx Inc | Terapias multifuncionais de célula imunológica |
| CN118679180A (zh) | 2021-11-15 | 2024-09-20 | 阿奇利克斯股份有限公司 | 包含d结构域的多肽及其用途 |
| KR20250129817A (ko) | 2022-11-29 | 2025-08-29 | 아르셀엑스, 인크. | D-도메인 함유 폴리펩티드 및 그의 용도 |
-
2016
- 2016-04-04 SG SG11201708257UA patent/SG11201708257UA/en unknown
- 2016-04-04 CN CN201680032015.3A patent/CN107921090A/zh active Pending
- 2016-04-04 MX MX2017012679A patent/MX387517B/es unknown
- 2016-04-04 CN CN201680032016.8A patent/CN107708720A/zh active Pending
- 2016-04-04 BR BR112017021308-7A patent/BR112017021308A2/pt not_active Application Discontinuation
- 2016-04-04 SG SG10202007987QA patent/SG10202007987QA/en unknown
- 2016-04-04 PL PL16777107T patent/PL3280432T3/pl unknown
- 2016-04-04 HU HUE16777107A patent/HUE054435T2/hu unknown
- 2016-04-04 WO PCT/US2016/025868 patent/WO2016164305A1/en not_active Ceased
- 2016-04-04 ES ES16777109T patent/ES2901273T3/es active Active
- 2016-04-04 LT LTEP16777107.0T patent/LT3280432T/lt unknown
- 2016-04-04 CA CA2981616A patent/CA2981616C/en active Active
- 2016-04-04 AU AU2016246426A patent/AU2016246426B2/en active Active
- 2016-04-04 EA EA201792226A patent/EA201792226A1/ru unknown
- 2016-04-04 SM SM20210285T patent/SMT202100285T1/it unknown
- 2016-04-04 KR KR1020257009799A patent/KR20250048140A/ko active Pending
- 2016-04-04 HR HRP20210498TT patent/HRP20210498T1/hr unknown
- 2016-04-04 RS RS20210529A patent/RS61907B1/sr unknown
- 2016-04-04 US US15/564,319 patent/US10647775B2/en active Active
- 2016-04-04 JP JP2018503725A patent/JP6871232B2/ja active Active
- 2016-04-04 WO PCT/US2016/025880 patent/WO2016164308A1/en not_active Ceased
- 2016-04-04 EP EP21155053.8A patent/EP3903804A1/en active Pending
- 2016-04-04 ES ES16777107T patent/ES2866202T3/es active Active
- 2016-04-04 DK DK16777107.0T patent/DK3280432T3/da active
- 2016-04-04 EP EP16777107.0A patent/EP3280432B8/en active Active
- 2016-04-04 PT PT167771070T patent/PT3280432T/pt unknown
- 2016-04-04 CN CN202210256708.8A patent/CN115160438A/zh active Pending
- 2016-04-04 JP JP2018503726A patent/JP6873101B2/ja active Active
- 2016-04-04 US US15/564,325 patent/US10662248B2/en active Active
- 2016-04-04 CN CN202510559733.7A patent/CN120424177A/zh active Pending
- 2016-04-04 CA CA2981711A patent/CA2981711A1/en active Pending
- 2016-04-04 SI SI201631199T patent/SI3280432T1/sl unknown
- 2016-04-04 DK DK16777109.6T patent/DK3280433T3/da active
- 2016-04-04 PH PH1/2017/501834A patent/PH12017501834B1/en unknown
- 2016-04-04 KR KR1020177031697A patent/KR102788389B1/ko active Active
- 2016-04-04 EP EP16777109.6A patent/EP3280433B1/en active Active
- 2016-04-05 WO PCT/US2016/026054 patent/WO2016164369A2/en not_active Ceased
- 2016-04-05 US US15/564,430 patent/US20180209983A1/en not_active Abandoned
-
2017
- 2017-10-02 MX MX2021013161A patent/MX2021013161A/es unknown
- 2017-10-06 IL IL254907A patent/IL254907B/en active IP Right Grant
- 2017-10-11 ZA ZA2017/06875A patent/ZA201706875B/en unknown
-
2020
- 2020-01-24 US US16/751,730 patent/US20200362046A1/en not_active Abandoned
- 2020-03-13 US US16/817,755 patent/US11008397B2/en active Active
- 2020-03-20 US US16/824,809 patent/US12528872B2/en active Active
-
2021
- 2021-02-09 AU AU2021200810A patent/AU2021200810B2/en active Active
- 2021-04-13 US US17/228,817 patent/US12358995B2/en active Active
- 2021-04-15 JP JP2021068754A patent/JP7244567B2/ja active Active
- 2021-04-27 IL IL282704A patent/IL282704A/en unknown
- 2021-06-03 CY CY20211100483T patent/CY1124453T1/el unknown
-
2022
- 2022-12-22 US US18/145,169 patent/US20240043550A1/en active Pending
-
2023
- 2023-01-23 JP JP2023007753A patent/JP2023052563A/ja not_active Withdrawn
- 2023-08-22 AU AU2023219820A patent/AU2023219820B2/en active Active
-
2024
- 2024-03-26 JP JP2024049923A patent/JP2024075751A/ja active Pending
-
2025
- 2025-04-23 AU AU2025202871A patent/AU2025202871A1/en active Pending
- 2025-06-06 US US19/231,210 patent/US20250353920A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11008376B2 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| JP7068459B2 (ja) | Ｎｙｅｓｏ ｔｃｒ | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| HRP20210498T1 (hr) | De novo vezujuća domena koja sadrži polipeptide i njihova upotreba | |
| EP3472205B1 (en) | Chimeric antigen receptor | |
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| US11878035B2 (en) | T cell-antigen coupler with various construct optimizations | |
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| JP2020530989A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2023512452A (ja) | Ｂｃｍａ指向性細胞免疫療法組成物および方法 | |
| JP2024544559A5 (enExample) | ||
| JP2025527657A (ja) | Ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体とキメラ共刺激受容体との組み合わせ物 | |
| JP2021525068A5 (enExample) | ||
| JP7174144B2 (ja) | Ｈａ－１特異的ｔ細胞受容体およびその使用 | |
| JP2023542208A (ja) | Ｍａｇｅ－ａ３特異的ｔ細胞受容体およびその使用 | |
| CN115873801A (zh) | 工程化免疫细胞及其用途 | |
| JP2024535740A5 (enExample) | ||
| NZ736022B2 (en) | De novo binding domain containing polypeptides and uses thereof | |
| HK40054580A (en) | Trifunctional t cell-antigen coupler and methods and uses thereof | |
| NZ805407A (en) | D-domain containing polypeptides and uses thereof | |
| HK1234091A1 (en) | Trifunctional t cell-antigen coupler and methods and uses thereof |